
Search
Selected Filter
Filter Results
Displaying 31–40 of 204 diseases results
-
Dec 20, 2024
The company is also planning to conduct the clinical trial at sites in the EU.
-
Dec 20, 2024
Eye on the Cure Podcast | Episode 78: Dr. Sheldon Rowan
Dr. Rowan talks about the impact of the glycemic index, microbiome, and diet on the development of age-related macular degeneration and optimization of overall retinal health.
-
Dec 16, 2024
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Dec 16, 2024
Staying True to Music, Family, and Advocacy
Music duo Andrew & Polly have earned a GRAMMY nomination for their children’s album “Ahhhhh!” while also championing disability awareness and inclusivity. Andrew’s experience with Stargardt disease fuels their advocacy, inspiring others through their music, podcast, and dedication to research and community support.
-
Dec 13, 2024
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Known as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
Dec 6, 2024
Eye on the Cure Podcast | Episode 77: Dr. Bob Bell
Dr. Bell, the CSO of Ascidian Therapeutics, talks about STELLAR, the company’s Phase ½ clinical trial for its emerging RNA-rewriting therapy for Stargardt disease (ABCA4 mutations).
-
Nov 15, 2024
Eye on the Cure Podcast | Episode 76: The Lemay-Pelletier Family
When the Lemay-Pelletier family from Montreal learned that three of their four children were losing vision from retinitis pigmentosa, they made the bold decision to spend 15 months traveling the world to give their kids as many visual memories as possible.
-
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Nov 13, 2024
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.